SRRK•benzinga•
Scholar Rock Initiates Phase 2 EMBRAZE Trial Of Apitegromab In Obesity And Announces New Preclinical Data Showing SRK-439 Is 'more potent than an anti-ActRII antibody in maintaining lean mass in diet-induced obesity (DIO) mice'
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 22, 2024 by benzinga